AbbVie Inc. $ABBV Shares Acquired by Alpha Cubed Investments LLC

Key Points

• Alpha Cubed Investments increased its stake in AbbVie by 19.1% in Q4 to 55,654 shares worth $12.72 million, and institutional investors own roughly 70.23% of the stock.
• Q1 beat and raised guidance: AbbVie reported EPS of $2.65 (vs. $2.59 est.) and $15B revenue (vs. $14.72B est.), sparking a rally; analysts' consensus is a "Moderate Buy" with an average price target of $252.90, though some firms cut targets to $230 while others keep buy ratings up to $275.
• AbbVie declared a quarterly dividend of $1.73 ($6.92 annualized, ~3.4% yield) despite a reported payout ratio of 340.89%, and company insiders have recently sold notable positions (e.g., EVP sold 22,381 shares).

Alpha Cubed Investments LLC boosted its holdings in AbbVie Inc. (NYSE:ABBV - Free Report) by 19.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 55,654 shares of the company's stock after acquiring an additional 8,913 shares during the quarter. Alpha Cubed Investments LLC's holdings in AbbVie were worth $12,716,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the business. Weil Company Inc. increased its position in AbbVie by 2.3% in the 3rd quarter. Weil Company Inc. now owns 2,026 shares of the company's stock valued at $469,000 after acquiring an additional 46 shares during the period. Hardin Capital Partners LLC increased its position in AbbVie by 1.4% in the 4th quarter. Hardin Capital Partners LLC now owns 3,321 shares of the company's stock valued at $759,000 after acquiring an additional 46 shares during the period. Inlet Private Wealth LLC increased its position in AbbVie by 0.3% in the 3rd quarter. Inlet Private Wealth LLC now owns 17,001 shares of the company's stock valued at $3,937,000 after acquiring an additional 47 shares during the period. D.B. Root & Company LLC increased its position in AbbVie by 4.3% in the 3rd quarter. D.B. Root & Company LLC now owns 1,152 shares of the company's stock valued at $267,000 after acquiring an additional 47 shares during the period. Finally, Redhawk Wealth Advisors Inc. increased its position in AbbVie by 1.5% in the 4th quarter. Redhawk Wealth Advisors Inc. now owns 3,162 shares of the company's stock valued at $722,000 after acquiring an additional 47 shares during the period. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms recently commented on ABBV. UBS Group lowered their target price on AbbVie from $240.00 to $230.00 and set a "neutral" rating on the stock in a research report on Thursday, February 5th. Citigroup lowered their price target on AbbVie from $235.00 to $230.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 27th. Guggenheim reiterated a "buy" rating and set a $249.00 price target on shares of AbbVie in a research report on Friday, May 1st. Canaccord Genuity Group lifted their price target on AbbVie from $262.00 to $265.00 and gave the company a "buy" rating in a research report on Thursday, April 30th. Finally, Berenberg Bank set a $275.00 price target on AbbVie in a research report on Tuesday, January 20th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $252.90.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q1 beat and raised guidance spurred a rally: AbbVie reported stronger‑than‑expected Q1 results and lifted 2026 guidance, which pushed the stock higher in early May as investors reassessed growth prospects from Skyrizi, Rinvoq and the pipeline. ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?
• Positive Sentiment: Analyst and retail attention following the quarter: Coverage from Zacks highlights the company as a top‑searched/“trending” stock, reflecting elevated investor interest after the beat — attention that can amplify moves on earnings or guidance news. ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?
• Positive Sentiment: Dividend appeal remains strong: Multiple income‑focused outlets continue to list AbbVie as a high‑yield dividend candidate, supporting demand from dividend investors despite valuation considerations. Want to Collect a High Dividend Every Month? Invest in These 3 Stocks
• Neutral Sentiment: Positive clinical and real‑world data showcased at DDW: AbbVie presented long‑term and real‑world evidence for SKYRIZI (risankizumab) and RINVOQ (upadacitinib) in IBD, which supports the commercial outlook but will take time to materially change revenue trajectory. AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®
• Neutral Sentiment: Industry tech/AI events mention AbbVie involvement: Participation in life‑science AI forums signals digital investment but is unlikely to move near‑term fundamentals. Zifo's SiEE Boston Summit Charts New Roadmap for 'Practical AI' in Life Sciences, Bridging the Gap Between Business Vision and Lab Reality
• Negative Sentiment: Regulatory/manufacturing setback for a wrinkle treatment: The U.S. FDA declined to approve AbbVie’s wrinkle product over manufacturing concerns (reported April 23), a near‑term headwind that can pressure sentiment and highlight execution risk on noncore franchises. US FDA declines to approve AbbVie's wrinkle treatment due to manufacturing concerns (April 23)

AbbVie Stock Performance

Shares of ABBV stock opened at $206.12 on Wednesday. AbbVie Inc. has a 1 year low of $176.57 and a 1 year high of $244.81. The stock has a market cap of $364.46 billion, a PE ratio of 101.54, a price-to-earnings-growth ratio of 0.72 and a beta of 0.32. The business's fifty day moving average is $214.17 and its 200-day moving average is $221.34.

AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.06. The business had revenue of $15 billion during the quarter, compared to analyst estimates of $14.72 billion. AbbVie had a negative return on equity of 911.57% and a net margin of 5.79%.The company's revenue was up 12.4% compared to the same quarter last year. During the same period last year, the company posted $2.46 EPS. Equities research analysts predict that AbbVie Inc. will post 14.3 earnings per share for the current year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 annualized dividend and a dividend yield of 3.4%. AbbVie's dividend payout ratio (DPR) is currently 340.89%.

Insider Buying and Selling at AbbVie

In other news, EVP Perry C. Siatis sold 22,381 shares of the firm's stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the sale, the executive vice president directly owned 38,137 shares of the company's stock, valued at $8,771,510. This trade represents a 36.98% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP David Ryan Purdue sold 5,230 shares of the firm's stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the sale, the senior vice president directly owned 2,654 shares of the company's stock, valued at approximately $619,868.24. This represents a 66.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 0.06% of the company's stock.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.